Efficient identification of neoantigen-specific T-cell responses in advanced human ovarian cancer. Issue 1 (20th June 2019)

• Record Type: Journal Article
• Authors: Liu, Song; Matsuzaki, Junko; Wei, Lei; Tsuji, Takemasa; Battaglia, Sebastiano; Hu, Qiang; Cortes, Eduardo; Wong, Laiping; Yan, Li; Long, Mark; Miliotto, Anthony; Bateman, Nicholas W.; Lele, Shashikant B.; Chodon, Thinle; Koya, Richard C.; Yao, Song; Zhu, Qianqian; Conrads, Thomas P.; Wang, Jianmin; Maxwell, George L.; Lugade, Amit A.; Odunsi, Kunle
• Is Part Of: Journal for immunotherapy of cancer. Volume 7:Issue 1(2019)
• Publication Date: 2019-06-20
• Subjects: Neoantigen -- Ovarian cancer -- CD4+ T-cells -- CD8+ T-cells -- Anti-tumor effect -- T-cell receptor -- Gene therapy; Cancer -- Immunotherapy -- Periodicals; Cancer -- Immunological aspects -- Periodicals; Tumors -- Immunological aspects -- Periodicals; Immunotherapy -- Periodicals; 616.99406105
• DOI: 10.1186/s40425-019-0629-6
• Languages: English
• ISSNs: 2051-1426

Abstract

Abstract : Background: Efficient identification of neoantigen-specific T-cell responses in epithelial ovarian cancer (EOC) remains a challenge. Existing investigations of spontaneous T-cell response to tumor neoepitope in EOC have taken the approach of comprehensive screening all neoantigen candidates, with a validation rate of 0.5–2%. Methods: Whole-exome and transcriptome sequencing analysis of treatment-naive EOC patients were performed to identify neoantigen candidates, and the immunogenicity of prioritized neoantigens was evaluated by analyzing spontaneous neoantigen-specfic CD4 + and CD8 + T-cell responses in the tumor and/or peripheral blood. The biological relevance of neoantigen-specific T-cell lines and clones were analyzed by evaluating the capacity of autologous ovarian tumor recognition. Genetic transfer of T-cell receptor (TCR) from these neoantigen-specific T-cell clones into peripheral blood T-cells was conducted to generate neoepitope-specific T-cells. The molecular signature associated with positive neoantigen T-cell responses was investigated, and the impacts of expression level and lymphocyte source on neoantigen identification were explored. Results: Using a small subset of prioritized neoantigen candidates, we were able to detect spontaneous CD4 + and/or CD8 + T-cell responses against neoepitopes from autologous lymphocytes in half of treatment-naïve EOC patients, with a significantly improved validation rate of 19%. Tumors from patients exhibiting neoantigen-specific T-cell responses exhibited a signature of upregulated antigen processing and presentation machinery, which was also associated with favorable patient survival in the TCGA ovarian cohort. T-cells specific against two mutated cancer-associated genes, NUP214 and JAK1, recognized autologous tumors . Gene-engineering with TCR from these neoantigen-specific T-cell clones conferred neoantigen-reactivity to peripheral T-cells. Conclusions: Our study demonstrated the feasibility of efficiently identifying both CD4 + and CD8 + neoantigen-specific T-cells in EOC. Autologous lymphocytes genetically engineered with tumor antigen-specific TCR can be used to generate cells for use in the personalized adoptive T-cell transfer immunotherapy.